Johna Norton Biography and Net Worth

Johna Norton is executive vice president of Global Quality for Eli Lilly and Company.

Johna joined Lilly in 1990 as an analytical chemist. She went on to hold positions with increasing responsibility in quality assurance and quality control, supporting manufacturing and process development at both Lilly facilities and with Lilly’s external manufacturing partners. Throughout her career, she has worked at multiple Lilly manufacturing sites, including sites in Indiana, Ireland and Puerto Rico. Prior to her current role, Johna was vice president, Quality, for Lilly’s Active Pharmaceutical Ingredient manufacturing network, Puerto Rico manufacturing, and Product Research and Development.

She holds a Bachelor of Science in chemistry from Gannon University and a Master’s in analytical chemistry from Miami University.

In 2017, FiercePharma named Johna one of the Top Women in Life Sciences.

She serves on the board of directors for United Way of Central Indiana.

What is Johna Norton's net worth?: The estimated net worth of Johna Norton is at least $19.16 million as of June 3rd, 2024. Norton owns 25,428 shares of Eli Lilly and Company stock worth more than $19,157,709 as of November 21st. This net worth evaluation does not reflect any other assets that Norton may own. Learn More about Johna Norton's net worth.
How do I contact Johna Norton?: The corporate mailing address for Norton and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Johna Norton's contact information.
Has Johna Norton been buying or selling shares of Eli Lilly and Company?: Johna Norton has not been actively trading shares of Eli Lilly and Company in the last ninety days. Most recently, Johna Norton sold 7,056 shares of the business's stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a transaction totalling $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares of the company's stock, valued at $20,835,194.64. Learn More on Johna Norton's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, insiders at the sold shares 26 times. They sold a total of 1,410,659 shares worth more than $1,192,819,015.29. The most recent insider tranaction occured on November, 8th when CAO Donald A Zakrowski sold 900 shares worth more than $723,042.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 11/8/2024.

Johna Norton Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/3/2024	Sell	7,056	$819.38	$5,781,545.28	25,428
6/14/2023	Sell	1,647	$444.29	$731,745.63	31,761

Johna Norton Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $753.41

$735.46

$757.37

50 Day Range

MA: $872.25

$727.57

$935.09

2 Week Range

Now: $753.41

$561.65

$972.53

Volume

5,116,185 shs

Average Volume

3,185,802 shs

Market Capitalization

$715.22 billion

P/E Ratio

81.45

Dividend Yield

0.72%

Beta

0.43

Top "Sleeping Giant" Crypto In The Market Now

From Crypto 101 Media | Ad

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late